AMANTA vs NEPHROPLUS: Stock Comparison

AMANTA vs NEPHROCARE HEALTH SERV LUpdated 16 Jun 26, 4:08 PM ISTNSE & company filings

NEPHROCARE HEALTH SERV L is the larger company by market capitalisation. AMANTA shows a lower P/E and faster revenue growth, while NEPHROCARE HEALTH SERV L shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AMANTA leads 3; NEPHROPLUS leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AMANTANEPHROPLUS

Valuation lens

What price are you paying?

Market CapContext only
₹749 Cr
₹7,398 Cr
P/E RatioAMANTA has the lower reading
53.58x
96.91x
P/B RatioAMANTA has the lower reading
3.57x
6.67x
EPSNEPHROPLUS has the higher reading
₹0.85
₹1.25
Book ValueContext only
₹56.71
₹111.27
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
NEPHROPLUS is the larger company
₹7,398 Cr vs ₹749 Cr
P/E Ratio
AMANTA has a lower P/E
53.58x vs 96.91x
P/B Ratio
AMANTA has a lower P/B
3.57x vs 6.67x
EPS
NEPHROPLUS has higher earnings per share
₹1.25 vs ₹0.85
Revenue Growth (TTM YoY)
AMANTA has faster revenue growth
6.8% vs 0%
EPS Growth (TTM YoY)
NEPHROPLUS has faster EPS growth
0% vs -23.4%
Qtr Sales Growth
NEPHROPLUS has stronger quarterly sales growth
-39.53% vs -76.08%
Qtr Profit Growth
NEPHROPLUS has stronger quarterly profit growth
-60.71% vs -77.74%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAMANTANEPHROPLUS
SectorHealthcare
IndustryPharmaceuticals

Price

MetricAMANTANEPHROPLUS
Live Price₹150.27₹737.65
Day Change-4.37%0.33%
Volume3.82 L17,398
52-Week High₹164₹781.5
52-Week Low₹92₹446
Distance from 52W High-8.37%-5.61%

Valuation

MetricAMANTANEPHROPLUS
Market Cap₹749 Cr₹7,398 Cr
P/E Ratio53.58x96.91x
P/B Ratio3.57x6.67x
EPS₹0.85₹1.25
Book Value₹56.71₹111.27
Dividend Yield0%0%

Growth

MetricAMANTANEPHROPLUS
Revenue Growth (TTM YoY)6.8%0%
EPS Growth (TTM YoY)-23.4%0%
Qtr Sales Growth-76.08%-39.53%
Qtr Profit Growth-77.74%-60.71%

Profitability & Leverage

MetricAMANTANEPHROPLUS
ROE6.75%10.88%
ROCE7.89%13.58%
Net Margin5.17%7.69%
Operating Margin14.55%14.87%
Debt to Equity1.06x0.07x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAMANTANEPHROPLUS
Promoter Holding26.87% 0.06 pp21.07%
FII Holding0.43% 0.42 pp8.78% 1.16 pp
DII Holding12.92% 0.04 pp9.05% 0.4 pp
Public Holding22.85% 0.29 pp18.32% 0.76 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMANTA and NEPHROCARE HEALTH SERV L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.